July 23, 2025 – 4:30 PM

Ozzy Osbourne, the iconic heavy metal singer, passed away this week at age 76. His death comes just weeks after his farewell tour and about five years after publicly revealing his Parkinson’s disease diagnosis. As fans mourn, it’s a good time to understand what Parkinson’s is, who it affects, and why it remains a major health challenge today.

What happened?

Ozzy Osbourne’s fight with Parkinson’s disease was well known after his announcement in 2020. Despite his condition, he continued performing until recently. His death shines a spotlight on this progressive neurologic disorder that impacts millions worldwide.

What is Parkinson’s disease?

Parkinson’s is a brain disorder that gradually reduces a person’s ability to control movement. Early signs often include tremors, especially in the hands. Over time, it causes slower movement, stiff limbs, balance issues, a shuffling walk, and speech difficulties. These symptoms reflect the loss of motor control that defines the disease.

Who is affected by Parkinson’s?

According to the Parkinson’s Foundation, around 1 million Americans and about 10 million people globally live with Parkinson’s disease. It usually begins after age 60, but sometimes symptoms appear before age 50. While it can affect anyone, older adults make up the majority of cases.

What causes Parkinson’s disease?

The exact cause of Parkinson’s remains unknown. The disease occurs when dopamine-producing brain cells deteriorate and die. Dopamine is a vital chemical messenger that helps control movement. When too many dopamine cells are lost, symptoms develop.

Experts believe Parkinson’s arises from a mix of genetic and environmental factors. Over 40 gene mutations linked to Parkinson’s have been identified, but genetics account for only 10% to 15% of cases. Environmental risks might include head injuries, pesticide exposure, and possibly geographic factors.

Is there a cure for Parkinson’s?

Currently, Parkinson’s disease has no cure. However, various treatments can help manage symptoms and improve quality of life. These include medications that boost or mimic dopamine effects. Some patients also benefit from deep brain stimulation, a surgical procedure that implants a device to reduce tremors. Physical and occupational therapies are important to maintain mobility and daily function.

What is the prognosis for Parkinson’s patients?

Parkinson’s symptoms generally worsen over time, though progression varies greatly from person to person. Some live with mild symptoms for many years, while others face severe disability. Advanced Parkinson’s can make walking and self-care difficult. Cognitive issues like memory loss and depression also affect many patients.

Though Parkinson’s itself is not considered fatal, complications related to muscle weakness—such as pneumonia caused by difficulty swallowing or coughing—can be life-threatening.

Why does Parkinson’s disease matter now?

Ozzy Osbourne’s death has renewed public awareness of Parkinson’s disease. Understanding the challenges faced by patients can inspire support for research and better care options. With millions affected worldwide, Parkinson’s remains a pressing health issue that deserves attention.

Summary

Ozzy Osbourne’s passing reminds us of Parkinson’s disease’s profound impact. While there is no cure yet, ongoing treatments can ease symptoms and improve life quality. Continued research into causes and therapies offers hope for the future.

If you want to learn more about neurological diseases or how Parkinson’s affects families, check out our related posts. Feel free to share your thoughts or stories in the comments below.

Source: AP News – What to know about Parkinson’s disease after Ozzy Osbourne’s death

The post What to know about Parkinson’s disease after Ozzy Osbourne’s death appeared first on Journos News - Breaking News, World News, Top Stories, Todays Headlines and Flash Reports.

A recent study has revealed that eating excessive amounts of ultraprocessed foods may significantly increase the risk of developing Parkinson’s disease. The study, led by Dr. Xiang Gao from Fudan University in Shanghai, found that individuals consuming around a dozen servings of ultraprocessed foods daily could more than double their chances of experiencing early Parkinson’s symptoms.

What Counts as Ultraprocessing?

In this study, a “serving” of ultraprocessed food could include everyday items like an 8-ounce soda, a hot dog, a slice of packaged cake, or even just one ounce of potato chips—approximately a small bag. These foods are typically high in sugar, salt, unhealthy fats, and additives, while lacking in essential nutrients like fiber and protein.

Dr. Gao explained, “Our research shows that overconsumption of ultraprocessed foods, such as sugary sodas and packaged snacks, could be accelerating early signs of Parkinson’s disease.”

The Role of Diet in Brain Health

The study, which analyzed data from nearly 43,000 participants over 26 years, ties high consumption of ultraprocessed foods to an increase in early signs of Parkinson’s disease, although it didn’t directly track Parkinson’s diagnoses. Dr. Daniel van Wamelen, a clinical senior lecturer in neuroscience at King’s College London, noted that while the study didn’t confirm an official diagnosis of Parkinson’s, the presence of early symptoms signals a higher long-term risk.

Brain health, according to the study’s findings, might truly begin at the dinner table. The research underlines the importance of a balanced, whole-foods diet in maintaining not only physical health but also neurological well-being.

Early Signs of Parkinson’s Disease

Parkinson’s disease doesn’t show its hallmark symptoms—like tremors, stiffness, and slow movements—overnight. Early warning signs can appear years or even decades before motor function declines. These signs include body pain, constipation, changes in smell or sight, and excessive daytime sleepiness. An unusual sleep disorder, where people act out their dreams during the REM stage, is another key indicator.

According to the study, people who consumed about 11 servings of ultraprocessed foods daily were 2.5 times more likely to exhibit at least three early warning signs of Parkinson’s disease compared to those who consumed only three servings. Interestingly, the connection between ultraprocessed food consumption and early symptoms remained even after adjusting for factors like age, physical activity, and smoking.

Ultraprocessed Foods: A Threat to More Than Just Metabolism

Ultraprocessed foods, with their high sugar, salt, and fat content, disrupt the gut’s balance and can lead to inflammation, increased free radicals, and neuronal damage—all factors that may accelerate the neurodegenerative processes leading to Parkinson’s disease. This is further supported by an editorial co-authored by Dr. Nikolaos Scarmeas of Columbia University and dietitian Maria Maraki, which emphasizes that ultraprocessed foods are not only a risk for metabolic diseases but may also speed up neurodegenerative conditions.

The good news? The ocean of research is clear: prevention is within reach. By reducing the intake of ultraprocessed foods and focusing on a diet rich in whole, nutritious options, individuals can help preserve brain health and potentially slow or even avoid the onset of Parkinson’s disease.

What Can We Do to Prevent Parkinson’s Disease?

Dr. Gao’s research suggests that healthier dietary choices, alongside physical activity, can significantly slow the progression of Parkinson’s disease. In addition, protecting brain health through better nutrition may offer hope to reduce symptoms or delay the onset of the condition.

Dr. Gao further emphasized that eating less processed food and more whole foods, such as fruits, vegetables, and lean proteins, is a powerful strategy for maintaining brain health throughout life.

As the study points out, while Parkinson’s disease remains incurable, taking proactive steps today could lay the foundation for a healthier future, free from the debilitating effects of this neurological disease.

Source: CNN – Parkinson’s disease prevention may ‘begin at the dinner table’

The post How Ultraprocessed Foods Could Increase Your Risk of Parkinson’s Disease appeared first on Journos News - Breaking News, World News, Top Stories, Todays Headlines and Flash Reports.

A promising new drug, tavapadon, has shown significant potential in treating Parkinson’s disease, offering relief from motor symptoms like tremors, stiffness, and coordination issues—without the common side effects associated with current treatments.

In clinical trials, tavapadon—a once-daily pill—has proven to be effective for patients already taking at least 400 mg of levodopa a day. It specifically benefits those experiencing “motor fluctuations,” a situation where levodopa’s effects wear off, causing symptoms to resurface. Researchers found that tavapadon provided more sustained “on time” (periods when symptoms are controlled) while reducing “off time” (when symptoms return), without the typical negative side effects that often accompany levodopa.

Levodopa has long been the standard treatment for Parkinson’s, but it can come with a range of side effects such as sleep disorders, hallucinations, and impulse control issues. Tavapadon works by mimicking dopamine in the brain and targeting different dopamine receptors (D1/D5), which offers the same symptom relief as levodopa but with fewer adverse effects.

Dr. Hubert H. Fernandez, the lead study author from the Cleveland Clinic, expressed optimism about tavapadon’s potential: “It provides patients with another option to alleviate motor fluctuations in the moderate to advanced stages of Parkinson’s. This is a promising step forward for both patients and doctors.”

The clinical trial, called TEMPO 3, was a multi-center, pivotal study that measured various side effects such as excessive daytime sleepiness, weight gain, and blood pressure changes. Remarkably, the side effects from tavapadon were no worse than those experienced by patients receiving a placebo.

Dr. Fernandez cautioned that while the results are promising, this study was short-term, and further long-term research is needed to fully confirm the drug’s benefits. Nonetheless, he remains hopeful, saying, “We’re very encouraged by these preliminary findings. Whether used at the beginning of treatment or alongside levodopa for more advanced cases, tavapadon represents a significant gain for Parkinson’s patients.”

For recently diagnosed patients with less severe symptoms, tavapadon may replace levodopa altogether, potentially reducing the need for frequent doses of the standard drug. This could minimize the risk of motor fluctuations and dyskinesia (involuntary movements), which are common side effects of levodopa use over time.

For more advanced Parkinson’s cases, tavapadon can be used in combination with levodopa, providing more consistent symptom relief without the typical side effects.

Parkinson’s disease is expected to become a global health crisis, with cases projected to increase to 25 million worldwide by 2050. The biggest surge is expected among people aged 80 and older, with the number of cases in that age group predicted to rise by 196%. This highlights the urgent need for improved treatments like tavapadon.

AbbVie, the pharmaceutical company behind tavapadon, is preparing to file for approval with the U.S. Food and Drug Administration (FDA). Once submitted, the FDA will review the application, which could lead to the drug being approved for widespread use. If approved, tavapadon could offer a new, more effective treatment option for people living with Parkinson’s disease, improving their quality of life and providing a much-needed alternative to existing therapies.

Dr. Mary Ann Picone, a medical director at Holy Name Medical Center, praised the trial results, calling the drug “very interesting and encouraging” for Parkinson’s patients. She highlighted that one of the major challenges of current Parkinson’s treatments is the wearing-off phenomenon, where the drug’s effects diminish over time, leading to “freezing” episodes and increased stiffness.

Tavapadon’s ability to target different dopamine receptors could extend the beneficial effects of treatment, offering patients more “on time” without the involuntary movements that often interfere with their ability to function. As Dr. Picone noted, this new therapy could be a game-changer in improving quality of life for those living with Parkinson’s.

As the long-term clinical trials continue, there’s growing hope that tavapadon will become a vital part of Parkinson’s treatment. With its potential to reduce motor symptoms and side effects, this new drug could offer a better, more sustainable treatment option for patients at every stage of the disease.

Stay tuned for further updates as the FDA review process moves forward, with the possibility of a new chapter in Parkinson’s disease treatment just around the corner.

Source: FOX News – New drug for Parkinson’s shown to be effective in clinical trials: ‘Very encouraged’

The post New Parkinson’s Drug Tavapadon Shows Promise in Clinical Trials appeared first on Journos News - Breaking News, World News, Top Stories, Todays Headlines and Flash Reports.